...
search icon
ptgx-img

Protagonist Therapeutics Inc, Common Stock

PTGX

NMQ

$42.01

-$2.27

(-5.13%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$2.83B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
10.4681
Volume info-icon
This is the total number of shares traded during the most recent trading day.
807.79K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.64
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$25.75 L
$60.6 H
$42.01

About Protagonist Therapeutics Inc, Common Stock

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FramePTGXSectorS&P500
1-Week Return-7.91%-3.69%1.67%
1-Month Return-2.78%-0.25%11.74%
3-Month Return11.28%-8.82%-7.11%
6-Month Return-11.74%-9.39%-4.66%
1-Year Return61.2%-5.13%9.11%
3-Year Return361.65%3.36%37%
5-Year Return418.32%35.62%98.26%
10-Year Return259.06%86.46%171.67%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue28.63M27.36M26.58M60.00M434.43M[{"date":"2020-12-31","value":6.59,"profit":true},{"date":"2021-12-31","value":6.3,"profit":true},{"date":"2022-12-31","value":6.12,"profit":true},{"date":"2023-12-31","value":13.81,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue-2.77M1.03M3.31M2.96M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":83.79,"profit":true},{"date":"2022-12-31","value":31.16,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":89.46,"profit":true}]
Gross Profit28.63M24.58M26.58M60.00M431.47M[{"date":"2020-12-31","value":6.63,"profit":true},{"date":"2021-12-31","value":5.7,"profit":true},{"date":"2022-12-31","value":6.16,"profit":true},{"date":"2023-12-31","value":13.91,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin100.00%89.86%100.00%100.00%99.32%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":89.86,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":99.32,"profit":true}]
Operating Expenses93.14M153.20M157.95M153.65M181.59M[{"date":"2020-12-31","value":51.29,"profit":true},{"date":"2021-12-31","value":84.37,"profit":true},{"date":"2022-12-31","value":86.98,"profit":true},{"date":"2023-12-31","value":84.61,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(64.52M)(125.84M)(131.37M)(93.65M)252.84M[{"date":"2020-12-31","value":-25.52,"profit":false},{"date":"2021-12-31","value":-49.77,"profit":false},{"date":"2022-12-31","value":-51.96,"profit":false},{"date":"2023-12-31","value":-37.04,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense(27.00K)737.00K8.04M27.60M52.88M[{"date":"2020-12-31","value":-0.05,"profit":false},{"date":"2021-12-31","value":1.39,"profit":true},{"date":"2022-12-31","value":15.2,"profit":true},{"date":"2023-12-31","value":52.2,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(64.84M)(125.55M)(127.39M)(78.95M)279.41M[{"date":"2020-12-31","value":-23.21,"profit":false},{"date":"2021-12-31","value":-44.93,"profit":false},{"date":"2022-12-31","value":-45.59,"profit":false},{"date":"2023-12-31","value":-28.26,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income Taxes1.30M(2.92M)(3.98M)(14.90M)4.22M[{"date":"2020-12-31","value":30.92,"profit":true},{"date":"2021-12-31","value":-69.29,"profit":false},{"date":"2022-12-31","value":-94.31,"profit":false},{"date":"2023-12-31","value":-353.03,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes(66.15M)(122.63M)(123.41M)(64.06M)275.19M[{"date":"2020-12-31","value":-24.04,"profit":false},{"date":"2021-12-31","value":-44.56,"profit":false},{"date":"2022-12-31","value":-44.85,"profit":false},{"date":"2023-12-31","value":-23.28,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income From Continuous Operations(66.15M)(125.55M)(127.39M)(140.48M)275.19M[{"date":"2020-12-31","value":-24.04,"profit":false},{"date":"2021-12-31","value":-45.62,"profit":false},{"date":"2022-12-31","value":-46.29,"profit":false},{"date":"2023-12-31","value":-51.05,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(66.15M)(122.63M)(123.41M)(78.95M)275.19M[{"date":"2020-12-31","value":-24.04,"profit":false},{"date":"2021-12-31","value":-44.56,"profit":false},{"date":"2022-12-31","value":-44.85,"profit":false},{"date":"2023-12-31","value":-28.69,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
EPS (Diluted)(2.02)(2.70)(2.60)(1.49)4.20[{"date":"2020-12-31","value":-48.1,"profit":false},{"date":"2021-12-31","value":-64.29,"profit":false},{"date":"2022-12-31","value":-61.9,"profit":false},{"date":"2023-12-31","value":-35.48,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

PTGX
Cash Ratio 8.84
Current Ratio 12.48

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

PTGX
ROA (LTM) 28.66%
ROE (LTM) 54.39%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

PTGX
Debt Ratio Lower is generally better. Negative is bad. 0.09
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.91

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

PTGX
Trailing PE 10.47
Forward PE 26.39
P/S (TTM) 6.49
P/B 4.18
Price/FCF NM
EV/R 5.55
EV/Ebitda 9.43
PEG NM

FAQs

What is Protagonist Therapeutics Inc share price today?

Protagonist Therapeutics Inc (PTGX) share price today is $42.01

Can Indians buy Protagonist Therapeutics Inc shares?

Yes, Indians can buy shares of Protagonist Therapeutics Inc (PTGX) on Vested. To buy Protagonist Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PTGX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Protagonist Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Protagonist Therapeutics Inc (PTGX) via the Vested app. You can start investing in Protagonist Therapeutics Inc (PTGX) with a minimum investment of $1.

How to invest in Protagonist Therapeutics Inc shares from India?

You can invest in shares of Protagonist Therapeutics Inc (PTGX) via Vested in three simple steps:

  • Click on Sign Up or Invest in PTGX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Protagonist Therapeutics Inc shares
What is Protagonist Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Protagonist Therapeutics Inc (PTGX) is $60.6. The 52-week low price of Protagonist Therapeutics Inc (PTGX) is $25.75.

What is Protagonist Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Protagonist Therapeutics Inc (PTGX) is 10.4681

What is Protagonist Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Protagonist Therapeutics Inc (PTGX) is 4.18

What is the Market Cap of Protagonist Therapeutics Inc?

The market capitalization of Protagonist Therapeutics Inc (PTGX) is $2.83B

What is Protagonist Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Protagonist Therapeutics Inc is PTGX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top